Get the Stockscreener App
2.38
6.67%
-0.17
After Hours:
2.39
0.01
+0.42%
Invivyd Inc stock is traded at $2.38, with a volume of 2.79M.
It is down -6.67% in the last 24 hours and up +6.73% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$2.55
Open:
$2.56
24h Volume:
2.79M
Relative Volume:
0.38
Market Cap:
$659.41M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-1.2143
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
-2.06%
1M Performance:
+6.73%
6M Performance:
+223.77%
1Y Performance:
+366.67%
1-Day Range:
$2.38
$2.59
1-Week Range:
$2.37
$2.59
52-Week Range:
$0.3546
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
209 CHURCH STREET, NEW HAVEN
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
2.38 | 706.52M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
View All
Invivyd Inc Stock (IVVD) Latest News
Aug Gainers: Why Heiwa Real Estate Co Ltd HZJ stock appears on watchlistsDividend Hike & Growth Focused Entry Reports - moha.gov.vn
Invivyd Inc. | Latest News & Innovations - shababeek.org
BTIG initiates Invivyd (IVVD) coverage, cites VYD2311’s superior market potential over Pemgarda - MSN
BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311’s Superior Market Potential Over Pemgarda - Insider Monkey
Invivyd (NASDAQ:IVVD) Trading Down 3.7%Here's Why - MarketBeat
Is Invivyd Inc. stock supported by strong fundamentalsChart Pattern Recognition & Minimal Risk High Reward - bollywoodhelpline.com
Does Invivyd’s (IVVD) Index Debut Reveal a Turning Point in Its Biotech Credibility? - Yahoo Finance
BTIG Reiterates Invivyd (IVVD) Buy Recommendation - Nasdaq
BTIG Research Upgrades Invivyd (NASDAQ:IVVD) to Strong-Buy - MarketBeat
Invivyd granted FDA fast track status for COVID therapy - MSN
FDA grants fast track designation for Invivyd’s COVID antibody By Investing.com - Investing.com Nigeria
Invivyd begins phase 3 trial of COVID prevention antibody VYD2311 By Investing.com - Investing.com Nigeria
US OPEN: Markets wobble amid low volumes and resilient GDP (23.12.2025) - XTB.com
Is Invivyd’s (IVVD) Index Debut Quietly Reframing Its Long-Term Biotech Positioning? - simplywall.st
Invivyd wins FDA fast track tag for COVID drug (IVVD:NASDAQ) - Seeking Alpha
Invivyd Says Vaccine-Alternative Antibody to Prevent COVID Gets FDA Fast Track Designation; Phase 3 Trial Launched - marketscreener.com
Invivyd’s COVID Antibody VYD2311 Receives FDA Fast Track - TipRanks
FDA grants fast track designation for Invivyd’s COVID antibody - Investing.com India
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - The Manila Times
Invivyd announces initiation of DECLARATION clinical trial, a phase 3 placebo-controlled pivotal study of VYD2311, a vaccine-alternative antibody to prevent Covid-19 - marketscreener.com
Invivyd stock rises after FDA grants Fast Track designation for COVID antibody - Investing.com Canada
Invivyd, Inc. Earns Fast Track Designation for COVID Antibody - TradingView — Track All Markets
Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody - TradingView — Track All Markets
Invivyd begins phase 3 trial of COVID prevention antibody VYD2311 - Investing.com
FDA puts COVID prevention shot alternative from Invivyd on Fast Track - Stock Titan
New antibody shot aims to offer vaccine-alternative protection from COVID - Stock Titan
Invivyd (IVVD): Assessing Valuation After S&P Biotechnology Select Industry Index Inclusion - Yahoo Finance
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
Invivyd announces proposed public offering of common stock - MSN
Invivyd, Inc. (IVVD): Advancing RSV antibody VBY329 amid analyst downgrade - MSN
Invivyd (NASDAQ:IVVD) Shares Gap UpShould You Buy? - MarketBeat
BTIG Initiates Invivyd at Buy With $10 Price Target - marketscreener.com
Invivyd stock initiated with Buy rating at BTIG on COVID antibody potential - Investing.com India
Invivyd stock initiated with Buy rating at BTIG on COVID antibody potential By Investing.com - Investing.com South Africa
BTIG Initiates Coverage of Invivyd (IVVD) with Buy Recommendation - Nasdaq
Invivyd, Inc.(NasdaqGM: IVVD) added to S&P Biotechnology Select Industry Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to NASDAQ Biotechnology Index - marketscreener.com
Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Invivyd Inc (IVVD) Stock News & Articles - 24/7 Wall St.
Aug Sentiment: Is Invivyd Inc. stock undervalued vs historical averagesWeekly Investment Summary & Smart Swing Trading Alerts - Улправда
How Invivyd Inc. stock reacts to Fed rate cutsProduct Launch & Technical Pattern Alert System - ulpravda.ru
Is Invivyd Inc. stock a good choice for value investorsJuly 2025 Gainers & Long Hold Capital Preservation Plans - Улправда
Is Invivyd Inc. stock undervalued vs historical averages2025 Historical Comparison & Fast Entry High Yield Tips - Улправда
How analysts rate Invivyd Inc. stock todayWeekly Stock Report & High Accuracy Investment Signals - DonanımHaber
How Recent Clinical Progress Is Rewriting the Story for Invivyd - Yahoo Finance
What sentiment indicators say about Invivyd Inc. stock2025 Sector Review & Smart Money Movement Tracker - Улправда
Invivyd, Inc. (IVVD): Advancing RSV Antibody VBY329 Amid Analyst Downgrade - Yahoo Finance
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MCLAUGHLIN KEVIN F | Director |
Nov 19 '25 |
Buy |
2.50 |
50,000 |
125,000 |
50,000 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):